Free Trial

OncoCyte Q4 2024 Earnings Report

OncoCyte logo
$2.79 -0.13 (-4.45%)
As of 10:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OncoCyte EPS Results

Actual EPS
$0.48
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.88
One Year Ago EPS
N/A

OncoCyte Revenue Results

Actual Revenue
$1.49 million
Expected Revenue
$0.16 million
Beat/Miss
Beat by +$1.33 million
YoY Revenue Growth
N/A

OncoCyte Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Remove Ads

OncoCyte Earnings Headlines

OncoCyte Co. (NASDAQ:OCX) Short Interest Update
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)
OncoCyte files to sell 10.61M shares of common stock for holders
OncoCyte initiated with a Buy at Lake Street
See More OncoCyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OncoCyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OncoCyte and other key companies, straight to your email.

About OncoCyte

OncoCyte (NASDAQ:OCX), a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

View OncoCyte Profile

More Earnings Resources from MarketBeat